SY-LB-57 is a highly effective agonist of bone morphogenetic protein (BMP) receptor signaling, suitable for studies of conditions such as bone fractures and pulmonary arterial hypertension [1].

SY-LB-57 (0.01-1000 μM, 24 h) induces cell proliferation at concentrations below 10 μM, with an IC50 value of 807.93 μM in C2C12 cells [1]. It increases Smad protein phosphorylation, promotes p-Smad nuclear translocation, activates the PI3K/Akt pathway, and induces cytoplasmic localization of p-Akt at 0.01-10 μM for 15-30 min [1]. Additionally, SY-LB-57 (0.01-10 μM, 24 h) shifts the cell cycle towards the S and G2/M phases [1]. Cell Viability Assay [1]: SY-LB-57 (0.01-1000 μM) increased cell viability in C2C12 cells by 280-50% at concentrations from 0.01 μM to 100 μM compared to control. Western Blot Analysis [1]: SY-LB-57 (0.01-10 μM) significantly increased Smad phosphorylation by 50-257% after 30 min and p-Akt expression by 667-1081% after 15 min. Cell Cycle Analysis [1]: SY-LB-57 (0.01-10 μM) shifted the cell cycle towards proliferation with a decrease in G0/G1 phase cells and an increase in S and G2/M phase cells.